newsfilter
← Latest News
Business Wire·

Foundation Medicine Collaborates With Merus to Advance Treatment Options in NRG1 Fusion-Driven Tumors Using Foundation Medicine's RNA Platform

Foundation Medicine, Inc. today announced a collaboration to develop Foundation Medicine's RNA platform as a companion diagnostic for Merus N.V.'s (NASDAQ:MRUS) bispecific antibody zenocutuzumab (Zeno) to treat patients